Avestria Ventures is an early-stage venture-capital firm based in the San Francisco Bay Area that invests in women’s health and female-led life-science businesses. It considers women’s health to include conditions that affect women exclusively, differently or disproportionately, ranging from reproductive health and menopause to cardiovascular disease and Alzheimer’s disease. The firm seeks evidence-based products and services that use technology or data to improve healthcare quality, access and costs, with attention to clinical adoption, reimbursement and scalable commercialization. Its portfolio spans medical devices, diagnostics, therapeutics and digital health. Linda Greub and Corinne Nevinny launched Avestria in2019; the current operating team includes managing partner Linda Greub and partner Tracy Dooley, alongside marketing, legal and social-media professionals, external advisers and separate limited-partner advisory committees.
Founded
2019
Type
Venture capital
Funds1
Avestria Ventures Fund II—
Avestria’s second venture fund supports early-stage women’s health and female-led life-science companies across devices, diagnostics, therapeutics and digital healthcare. The manager’s own website states that Fund II closed in July2024. The exact closing day, corpus and whether this was a first or final close are not disclosed on the primary source. Own FundII holdings include Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, Mercy BioAnalytics and Genome Medical.
Angelini Ventures
Avation Medical$— · 2024-02-01
Arboretum Ventures
Asahi Kasei Corp.
BNP Paribas Asset Management Alts
Novocuff$26M · 2024-07-17
Bpifrance
May Health$25M · 2024-05-13
JobsOhio Ventures
Joyance
Clarified Precision Medicine$1M · 2024-04-16
Kidron Capital
Laerdal Million Lives Fund
Medtronic
ShangBay Capital
Sofinnova Partners